MANE Stock Analysis: Veradermics | NYSE
Biotechnology | NYSE, USA | Market Cap: 5.420m USD | 12M Return: 214.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 63.0M
Warnings
Tailwinds
Seasonality 0.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Veradermics, Incorporated (NYSE: MANE) is a clinical-stage biopharmaceutical company developing therapeutics for dermatologic and aesthetic conditions. Founded in 2019 and headquartered in New Haven, Connecticut, the company maintains a pipeline centered on conditions such as pattern hair loss, common warts, alopecia areata, molluscum contagiosum, and atopic dermatitis.
Its lead candidate, VDPHL01, is an oral, non-hormonal treatment for pattern hair loss in both men and women, distinguishing it from commonly used hormonal therapies. The pipeline also includes VDMN, a dissolvable microarray patch for wart immunotherapy, along with VDAA for alopecia areata and VDMC for molluscum contagiosum.
As a clinical-stage biotech, Veradermics has no approved products on the market, and its business model relies on advancing candidates through clinical development with the goal of future commercialization or partnership. The company targets healthcare providers and clinicians serving both adult and pediatric dermatology patients.
- VDPHL01 Phase 3 results approach for pattern hair loss
- Pipeline advances across warts, alopecia, and molluscum indications
- Cash burn and dilution risk as clinical-stage biotech
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 24.39 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.15 > 3% & CFO -61.7m > Net Income -67.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 59.12 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (35.1m) vs prev -82.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.98 (Total Current Assets 397.1m - Total Current Liabilities 6.72m) / Total Assets 398.6m |
| B: -0.38 (Retained Earnings -150.7m / Total Assets 398.6m) |
| C: -0.31 (EBIT TTM -71.7m / Avg Total Assets 229.0m) |
| D: 58.35 (Book Value of Equity 391.9m / Total Liabilities 6.72m) |
| Altman-Z'' = 64.35 = AAA |
As of July 08, 2026, the stock is trading at USD 116.80 with a total of 384,797 shares traded. Over the past week, the price has changed by -5.49%, over one month by +29.32%, over three months by +105.96% and over the past year by +214.32%.
Current recommended Stop Loss: 106.70 (which is 8.6% or 1.2 ATR below the current price).
Veradermics has no consensus analysts rating.
P/B = 13.8756
Revenue TTM = 0.0 USD
EBIT TTM = -71.7m USD
EBITDA TTM = -71.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 4.00k USD (from shortLongTermDebtTotal, last fiscal year) (leases 4.00k already included)
Net Debt = -390.8m USD (calculated: Debt 4.00k - CCE 390.8m)
Enterprise Value = 5.03b USD (5.42b + Debt 4.00k - CCE 390.8m)
Interest Coverage Ratio = unknown (Ebit TTM -71.7m / Interest Expense TTM 0.0)
EV/FCF = -81.43x (Enterprise Value 5.03b / FCF TTM -61.8m)
FCF Yield = -1.23% (FCF TTM -61.8m / Enterprise Value 5.03b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 12.62 (Enterprise Value 5.03b / Total Assets 398.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.00k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -56.7m (EBIT -71.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 59.12 (Total Current Assets 397.1m / Total Current Liabilities 6.72m)
Debt / Equity = 0.00 (Debt 4.00k / totalStockholderEquity, last quarter 391.9m)
Debt / EBITDA = 5.45 (negative EBITDA) (Net Debt -390.8m / EBITDA -71.7m)
Debt / FCF = 6.33 (negative FCF - burning cash) (Net Debt -390.8m / FCF TTM -61.8m)
Total Stockholder Equity = 57.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.32% (Net Income -67.1m / Total Assets 398.6m)
RoE = -117.0% (Net Income TTM -67.1m / Total Stockholder Equity 57.4m)
RoCE = -18.30% (EBIT -71.7m / Capital Employed (Total Assets 398.6m - Current Liab 6.72m))
RoIC = -14.46% (negative operating profit) (NOPAT -56.7m / Invested Capital 391.9m)
WACC = 5.16% (E(5.42b)/V(5.42b) * Re(5.16%) + D(4.00k)/V(5.42b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -18.26 | Cagr: -89.42%
[DCF] Fair Price = unknown (Cash Flow -61.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.66 | Chg30d=-4.15% | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.65 | Chg30d=+1.79% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=-2.81 | Chg30d=+11.82% | Revisions=-25% | GrowthEPS=+97.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.04 | Chg30d=-1.20% | Revisions=+25% | GrowthEPS=-8.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +29% (up=3, down=1)